ClinicalTrials.gg
Not yet recruitingNCT06965738BOLTUpdated May 21, 2025

Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain

A Phase 2 interventional study of Buccal fat reconstruction and No buccal fat reconstruction in Tonsil Neoplasm, Oropharynx Neoplasm and Transoral Robotic Surgery, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Oropharyngeal Neoplasms with a site in Canada — 9 open to participants now, 14 under way, 5 of them phase 3. Oropharyngeal Neoplasms · Canada.

Planned enrollment
14th of 20
40 · median 76
Started
2025
with 2 others
Phase 2
6 of 25
4 open now
Primary completion
2027-04
later than 8 of 13 live
Registered
23rd of 25
by date
Lead sponsor
4 of 25
University Health Network, Toronto

Among the 25 studies in Oropharyngeal Neoplasms with a site in Canada, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 8 of the 13 other live ones, and was the 23rd registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

9 of the 25 studies in Oropharyngeal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Oropharyngeal Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to determine the pain intensity during rest and swallowing in patients undergoing transoral robotic surgery for tonsil lesions with and without buccal fat reconstruction. The main question it aims to answer is: does buccal fat after transoral robotic surgery reduce pain after surgery? Additional questions to be explored include if there is a difference in swallowing, complication rates, pain medication usage, and feeding tube usage. Participants will be asked to rate their pain and swallowing on a visual analogue scale after surgery. The group will be compared compared to a control group that undergoes transoral robotic surgery without buccal fat reconstruction.

Read the detailed description

Trans-oral robotic surgery (TORS) for oropharyngeal cancers have transformed how oropharyngeal cancers are managed, allowing for minimally invasive surgical access to remove tumors of the tonsil and base of tongue. While large incisions and open approaches can be avoided, oropharyngeal defects following TORS are traditionally left as an open wound to heal by secondary intention, resulting in significant postoperative pain, and possibly dysphagia and dehydration.

While this has been highlighted as a key outcome measure, studies on acute pain following TORS have not had any standardization regarding the timing of pain measurement, and pain assessment. Only one study has assessed pain during 'movement-related pain', such as swallowing, which has been advocated as a key metric. Most studies used a visual analogue scale, however, majority failed to describe the timing of pain assessment relative to administration of analgesia, time of day, or diet. Overall, pain ratings and opioid utilization were highly variable between studies resulting in pain ratings ranging widely from 2.5-8 in the first few days postoperatively.

Based on the current evidence, multimodal analgesia resulted in the lowest pain ratings following TORS, with those that included gabapentin, a COX-2 inhibitor and acetaminophen having excellent pain control in the early postoperative period. Using these regimens, Castellanos et al. found that postoperative opioid consumption significantly decreased in the first three postoperative days. Clayburgh, et al. identified that addition of perioperative corticosteroids was safe and significantly improved diet consistency, and decreased length of hospital stay, though pain scores were minimally affected.

No study thus far has assessed the impact of surgical interventions on postoperative pain and swallowing. This single center, phase II, randomized control trial aims to evaluate the impact of the buccal fat rotational flap on the postoperative pain following TORS.

03

Conditions studied

  • Tonsil Neoplasm
  • Oropharynx Neoplasm
  • Transoral Robotic Surgery

Keywords

  • Transoral Robotic Surgery
  • Buccal Fat
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18
  2. Require a transoral robotic lateral oropharyngectomy as a result of the following conditions :

    • Early - intermediate stage tonsillar squamous cell carcinoma (T1-2N0-1 p16+/- SCC of the palatine tonsils)
    • Early -intermediate stage salivary gland tumors of the palatine tonsils
    • based on FNA, Core , Punch biopsy
  3. Ability to understand and willing to sign a written

Exclusion criteria

Exclusion Criteria:

  1. History of prior head and neck squamous cell carcinoma, or prior head and neck radiotherapy
  2. Presence of retropharyngeal lymphadenopathy
  3. Presence of bilateral lymphadenopathy, or patients requiring bilateral neck dissections.
  4. Patients with trismus at baseline
  5. Patients with psychological risk factors for persistent opioid use or drug addiction
  6. Need for open surgery (transcervical lateral oropharyngectomy), free tissue transfer, or alternative regional flap.
  7. Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Transoral lateral oropharyngectomy alone

    Transoral lateral oropharyngectomy without buccal fat reconstruction

    Procedure: No buccal fat reconstruction

  • Experimental
    Transoral lateral oropharyngectomy with buccal fat reconstruction

    Transoral lateral oropharyngectomy with buccal fat reconstruction

    Procedure: Buccal fat reconstruction

Interventions

  • ProcedureBuccal fat reconstruction

    Ipsilateral buccal fat rotation flap for reconstruction of lateral oropharyngectomy defect

  • ProcedureNo buccal fat reconstruction

    No reconstruction of lateral oropharyngectomy defect

06

What researchers measure

Primary outcomes

  1. Postoperative pain during rest and swallowing

    Postoperative pain during rest and swallowing on visual analogue scale at multiple time points

    Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 1-3, postoperative day 7-10, postoperative day 21-28

Secondary outcomes

  1. Surgical Complications

    Surgical complications and adverse events within 30 days postoperatively using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC-AE v4.0)

    Time frame: 30 days postoperatively

  2. Opioid usage

    Determine opioid usage

    Time frame: 30 days postoperatively

  3. Postoperative Hemorrhage

    Postoperative hemorrhage after TORS

    Time frame: 30 days postoperatively

  4. Speech and Swallowing

    Determine postoperative speech and swallowing using the Performance Status Scale for Head and Neck (PSS-HN)

    Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 7-10, postoperative day 21-28

  5. Oral Diet

    Determine food consistencies achieved at short post-operative follow up (per PSS-HN)

    Time frame: Once each at the following timepoints: 1-2 week preoperatively, postoperative day 7-10, postoperative day 21-28

  6. Feeding Tube Placement

    Determine rate of feeding tube placement

    Time frame: 30 days postoperatively

  7. Blood Glucose

    Determine blood glucose levels

    Time frame: 30 days postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data, randomization, primary and secondary outcomes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: May 2027-May 2037

Access criteria: IPD can be shared on a case by case basis by contacting the principal investigator, data will be de-identified, extent of data will be determined and decided upon by the principal investigator, data will be shared via secure email and data transfer agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Apr 2027, 22 months later.

Of 63 non-industry phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 99. This study's planned 22 months is below that.

Counting every sponsor, half of 64 studies reached it within 63 months; a quarter within 49 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
May 11, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 1, 2027
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06965738
Responsible party
Christopher Yao (Principal Investigator, University Health Network, Toronto) — Principal investigator
First posted
May 11, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
May 21, 2025

Study contacts

Christopher Yao, MD FRCSC
Contact
christophermkl.yao@uhn.ca
(416) 340-3063
Michael Xie, MD FRCSC
Contact
michael.xie@uhn.ca
(416) 340-3063
Christopher Yao, MD FRCSC
principal investigator · University Health Network, Toronto
John R de Almeida, MD MSc FRCSC
study director · University Health Network, Toronto
Michael Xie, MD FRCSC
study chair · University Health Network, Toronto
Rosemary Martino, Ma MSc PhD
study chair · University Health Network, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion